Thinking of joining a study?

Register your interest

NCT03816865 | COMPLETED | Atrial Fibrillation


Fibrosis, Inflammation and Brain Health in Atrial Fibrillation.
Sponsor:

Oslo University Hospital

Information provided by (Responsible Party):

Anne Hege Aamodt

Brief Summary:

Protocol synopsis Sponsor: Oslo University Hospital Title: Fibrosis, inflammation and cerebral infarction in patients with atrial fibrillation Study Design: The study is an observational prospective study of atrial fibrillation patients undergoing direct-current cardioversion. Primary Objective: To assess the prevalence and causes of new silent cerebral ischemic lesions after programmed direct-current cardioversion using diffusion-weighted sequences in brain MRI (DWMRI). Secondary Objectives: To study the impact of inflammation measured by biomarkers and cardiac 18F-FDG-PET on the risk for new silent cerebral ischemic lesions after direct-current cardioversion for AF. To assess the impact of fibrosis measured by biomarkers on the risk for new silent cerebral ischemic lesions after direct-current cardioversion for AF. To assess cognitive and cerebral structural and metabolic changes after direct-current cardioversion for AF using cognitive assessments and cerebral and cardiac 18F-FDG-PET before and 12 months after treatment. Number of Subjects: 50 Study Centers: Østfold Hospital Trust Duration of Study Participation: * Enrollment: 18 months * Follow-up period: 12 months * Total Study Duration: 30 months Primary Endpoints: • Number of new small cerebral infarcts detected with DWMRI two weeks after direct current cardioversion. Secondary Endpoints: * Rate of AF recurrence within 1 year after direct current cardioversion * Change in levels of inflammation biomarkersfrom baseline to 12 months follow-up * Change in levels of fibrosis biomarkers from baseline to 12 months follow-up * Cognitive function at 12 months follow-up * Changes in uptake pattern on cerebral 18F-FDG-PET from baseline to 12 months follow-up * Changes in uptake pattern on cardiac 18F-FDG-PET from baseline to 12 months follow-up * Brain volume at 12 months follow-up * White matter volume 12 months follow-up * Grey matter volume 12 months follow-up * Cortical volume 12 months follow-up * RSI-derived diffusion parameters 12 months follow-up: fast apparent diffusion coefficient, extracellular water fraction, fractional anisotropy; free water fraction; intracranial volume; NAWM: normal appearing white matter; neurite density; RSI: restriction spectrum imaging; sADC: slow apparent diffusion coefficient;restricted fractional anisotropy; white matter lesions.

Condition or disease

Atrial Fibrillation

Stroke

Study Type : OBSERVATIONAL
Estimated Enrollment : 46 participants
Official Title : Fibrosis, Inflammation and Brain Health in Atrial Fibrillation. The Norwegian Atrial Fibrillation and Stroke Study
Actual Study Start Date : 2018-03-01
Estimated Primary Completion Date : 2023-12-31
Estimated Study Completion Date : 2024-03-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 80 Years
Sexes Eligible for Study: ALL
Criteria
1. Known atrial fibrillation
  • 2. Age \<80 years
  • 3. CHA2DS2-VASc ≤ 4
  • 4. Planned direct-current cardioversion
  • Exclusion criteria
    • 1. CHA2DS2-VASc \>4
    • 2. Life expectancy less than 1 year
    • 3. Patient otherwise not eligible for the study or adherent for follow-up (eg nonresident) or has concurrent disease affecting outcome (e.g. multiple sclerosis, cancer)

  • Fibrosis, Inflammation and Brain Health in Atrial Fibrillation.

    Location Details

    NCT03816865


    Please Choose a site



    How to Participate

    Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

    Locations


    Not yet recruiting

    Norway,

    Oslo University Hospital

    Oslo, Norway, 0424

    Not yet recruiting

    Norway,

    Østfold Hospital

    Sarpsborg, Norway,

    Loading...